Spyre Therapeutics (SYRE) Interest Coverage Ratio Growth (1y) (2016 - 2026)
Spyre Therapeutics (SYRE) Interest Coverage Ratio Growth (1y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | -60.44% |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | -347.04% |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | 787.12% |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 53.59% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | -32.04% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | 73.00% |
| 10 | Spyre Therapeutics | 263.95 Mn | 263.95 Mn | - | 87.02% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 87.02% |
| Dec 31, 2025 | -130,998.11% |
| Sep 30, 2025 | 45.95% |
| Jun 30, 2025 | -317.83% |
| Mar 31, 2025 | -214.09% |
| Dec 31, 2024 | -2.75% |
| Sep 30, 2024 | -1,636.95% |
| Dec 31, 2023 | 99.64% |
| Sep 30, 2023 | 1.38% |
| Dec 31, 2022 | -61.82% |
| Sep 30, 2022 | 86.46% |
| Jun 30, 2022 | 67.11% |
| Mar 31, 2022 | 99.15% |
| Dec 31, 2021 | -936.53% |
| Sep 30, 2021 | 93.41% |
| Jun 30, 2021 | 91.36% |
| Mar 31, 2021 | -13,971.72% |
| Dec 31, 2020 | 94.51% |
| Sep 30, 2020 | -264,306.27% |
| Jun 30, 2020 | -78,489.45% |